Mineralys CCO exercises options, sells 104K shares
Mineralys Therapeutics Chief Commercial Officer Eric Warren exercised stock options and sold shares in a planned transaction.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Mineralys Therapeutics Chief Commercial Officer Eric Warren exercised stock options and sold shares in a planned transaction. He exercised options for 104,124 shares of common stock at $13.24 per share and sold 104,124 shares at a weighted-average price of $25.8953 per share.
These trades were carried out under a Rule 10b5-1 stock selling plan adopted on March 27, 2026, indicating they were pre-scheduled. Following the transactions, Warren directly owns 38,400 shares of Mineralys common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 104,124 shares ($1.32M approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Warren Eric
Role
Chief Commercial Officer
Sold
104,124 shs ($2.70M)
Approx. gross sale proceeds
$2.70M
Approx. exercise cost
$1.38M
Approx. pre-tax spread
$1.32M
Share of Position Sold
73.1%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 104,124 | $0.00 | $0.00 |
| Exercise | Common Stock | 104,124 | $13.24 | $1.38M |
| Sale | Common Stock | 104,124 | $25.8953 | $2.70M |
Holdings After Transaction:
Stock Option — 252,876 contracts (Direct);
Common Stock — 38,400 shares (Direct)
Holdings Before and After:
Stock Option, 357,000 to 252,876 contracts (Direct);
Common Stock, 38,400 to 38,400 shares (Direct)
Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
- F1. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
- F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.8941 to $25.9100. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- F3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Key Figures
Shares sold: 104,124 shares
Sale price: $25.8953 per share
Option exercise price: $13.24 per share
+3 more
6 metrics
Shares sold
104,124 shares
Common stock sold on June 26, 2026
Sale price
$25.8953 per share
Weighted-average sale price for 104,124 shares
Option exercise price
$13.24 per share
Conversion price for 104,124 underlying shares
Shares after transactions
38,400 shares
Common stock directly owned after June 26, 2026
Option expiration
April 21, 2035
Expiration date of exercised stock option
Rule 10b5-1 plan date
March 27, 2026
Adoption date of stock selling plan
Key Terms
Rule 10b5-1 stock selling plan, weighted-average price, stock option, derivative security
4 terms
Rule 10b5-1 stock selling plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026."
weighted-average price financial
"The price reported in Column 4 is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
stock option financial
"The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Mineralys Therapeutics (MLYS) report for Eric Warren?
Mineralys Therapeutics reported that Chief Commercial Officer Eric Warren exercised stock options for 104,124 shares and sold 104,124 common shares. The transactions occurred on June 26, 2026, and were executed as part of a pre-arranged Rule 10b5-1 stock selling plan.
Were Eric Warren’s Mineralys Therapeutics (MLYS) stock sales under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state that Eric Warren’s transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Such plans allow insiders to schedule trades in advance, helping separate trading decisions from day-to-day market developments.
What are the details of Eric Warren’s exercised stock options in Mineralys Therapeutics (MLYS)?
Eric Warren exercised stock options covering 104,124 underlying shares of Mineralys common stock at a conversion price of $13.24 per share. The option expires on April 21, 2035, and vested 25% after one year, with the remainder vesting in 36 substantially equal monthly installments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
